BR112014024139A8 - administração de eritoran ou sais farmaceuticamente aceitáveis do mesmo para tratar infecções de ortomixovírus - Google Patents

administração de eritoran ou sais farmaceuticamente aceitáveis do mesmo para tratar infecções de ortomixovírus

Info

Publication number
BR112014024139A8
BR112014024139A8 BR112014024139A BR112014024139A BR112014024139A8 BR 112014024139 A8 BR112014024139 A8 BR 112014024139A8 BR 112014024139 A BR112014024139 A BR 112014024139A BR 112014024139 A BR112014024139 A BR 112014024139A BR 112014024139 A8 BR112014024139 A8 BR 112014024139A8
Authority
BR
Brazil
Prior art keywords
eritoran
administration
pharmaceutically acceptable
acceptable salts
treat
Prior art date
Application number
BR112014024139A
Other languages
English (en)
Other versions
BR112014024139A2 (pt
Inventor
Ann Shirey Kari
Vogel Stefanie
Original Assignee
Univ Maryland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Maryland filed Critical Univ Maryland
Publication of BR112014024139A2 publication Critical patent/BR112014024139A2/pt
Publication of BR112014024139A8 publication Critical patent/BR112014024139A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
BR112014024139A 2012-03-28 2013-03-04 administração de eritoran ou sais farmaceuticamente aceitáveis do mesmo para tratar infecções de ortomixovírus BR112014024139A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261616784P 2012-03-28 2012-03-28
US201361771339P 2013-03-01 2013-03-01
PCT/US2013/028856 WO2013148072A1 (en) 2012-03-28 2013-03-04 Administration of eritoran or pharmaceutically acceptable salts thereof to treat orthomyxovirus infections

Publications (2)

Publication Number Publication Date
BR112014024139A2 BR112014024139A2 (pt) 2017-06-20
BR112014024139A8 true BR112014024139A8 (pt) 2018-01-16

Family

ID=47844539

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014024139A BR112014024139A8 (pt) 2012-03-28 2013-03-04 administração de eritoran ou sais farmaceuticamente aceitáveis do mesmo para tratar infecções de ortomixovírus

Country Status (13)

Country Link
US (2) US9132141B2 (pt)
EP (1) EP2830631B1 (pt)
JP (2) JP6081574B2 (pt)
KR (1) KR20140139063A (pt)
CN (1) CN104321061B (pt)
AU (1) AU2013240456B2 (pt)
BR (1) BR112014024139A8 (pt)
CA (1) CA2868458A1 (pt)
IL (2) IL234777A (pt)
MX (1) MX358470B (pt)
RU (1) RU2636622C2 (pt)
TW (1) TWI594755B (pt)
WO (1) WO2013148072A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014413902A1 (en) * 2014-12-08 2017-06-15 The University Of Queensland Methods and compositions for treating or preventing flavivirus infections
AU2015360255B2 (en) 2014-12-12 2019-02-07 The Feinstein Institute For Medical Research Treatment of HMGB1-mediated inflammation
WO2021207218A1 (en) * 2020-04-06 2021-10-14 Eisai R&D Management Co., Ltd. Treatment of nidovirales infection with eritoran

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681824A (en) 1995-06-05 1997-10-28 Eisai Co., Ltd. Substituted liposaccharides useful in the treatment and prevention of endotoxemia
US20030130212A1 (en) * 1999-01-14 2003-07-10 Rossignol Daniel P. Administration of an anti-endotoxin drug by intravenous infusion
IL151314A0 (en) 2000-02-18 2003-04-10 Eisai Co Ltd Micelles, methods for their preparation and methods for delivery of micelles to patients
RU2289410C2 (ru) * 2001-04-04 2006-12-20 Корикса Корпорейшн Профилактика и лечение инфекционных и других заболеваний с помощью соединений, основанных на моно- и дисахаридах
US7727974B2 (en) * 2001-08-10 2010-06-01 Eisai R & D Management Co., Ltd. Methods of reducing the severity of mucositis
EP1601661A2 (en) * 2003-03-05 2005-12-07 Eisai Co., Ltd Compositions and methods for preventing and treating endotoxin-related diseases and conditions
US20060211752A1 (en) * 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
KR20080038085A (ko) * 2005-05-13 2008-05-02 에자이 가부시키가이샤 구강과 위장관 점막염의 악화를 경감하는 방법
US20100015125A1 (en) * 2005-06-17 2010-01-21 University Of Rochester Methods and compositions for enhancing immune memory by blocking intrahepatic activated t cell deletion
AR056591A1 (es) 2005-10-28 2007-10-10 Vaxinnate Corp Polipeptidos ligandos para receptor 4 simil toll (tlr4)
GB0605247D0 (en) * 2006-03-15 2006-04-26 Chiron Srl Compositions and methods for immunisation
WO2007139150A1 (ja) 2006-05-30 2007-12-06 The University Of Tokushima ＴＮＦα阻害物質を含有してなる抗インフルエンザウイルス剤
US8207144B2 (en) 2006-11-22 2012-06-26 Eisai R & D Management Co., Ltd. Sodium salt of disaccharide compound, production method and use of same
US20110201569A1 (en) 2009-09-16 2011-08-18 Heidi Ehrentraut Methods For Treating Myocardial Disorders

Also Published As

Publication number Publication date
CA2868458A1 (en) 2013-10-03
US20160022717A1 (en) 2016-01-28
JP2015512397A (ja) 2015-04-27
MX358470B (es) 2018-08-22
WO2013148072A1 (en) 2013-10-03
AU2013240456B2 (en) 2017-04-13
US9132141B2 (en) 2015-09-15
CN104321061B (zh) 2017-10-24
JP6081574B2 (ja) 2017-02-15
RU2636622C2 (ru) 2017-11-24
TW201402127A (zh) 2014-01-16
AU2013240456A1 (en) 2014-10-09
CN104321061A (zh) 2015-01-28
BR112014024139A2 (pt) 2017-06-20
IL234777A (en) 2017-02-28
TWI594755B (zh) 2017-08-11
JP2017081993A (ja) 2017-05-18
EP2830631A1 (en) 2015-02-04
IL250201A0 (en) 2017-03-30
EP2830631B1 (en) 2017-11-22
KR20140139063A (ko) 2014-12-04
RU2014138880A (ru) 2016-05-20
MX2014011520A (es) 2015-11-16
US20130261076A1 (en) 2013-10-03

Similar Documents

Publication Publication Date Title
NL300947I2 (nl) Bictegravir of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder bictegravirnatrium
BR112015003376A8 (pt) composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e usos de quantidade eficiente de composto ou sal farmaceuticamente aceitável do mesmo ou composição farmacêutica
CO6852076A2 (es) Composiciones farmacéuticas inhalables
BR112014020345A2 (pt) Medicamentos antivirais para o tratamento da infecção por arenavírus
CL2016001110A1 (es) Inhibidores de la replicación del virus de la gripe
EA201491486A1 (ru) Производные пиперидинопиримидина для лечения вирусных инфекций
BR112015003125A2 (pt) ingrediente hidrante cosmético ou7 farmacêutico
HK1205696A1 (en) Compositions for topical treatment of microbial infections
CO6960541A2 (es) Nueva composición farmacéutica resistente al abuso para el tratamiento de la dependencia de opioides
BR112015003345A2 (pt) protocolo pandêmico para atendimento de emergência
CL2014001883A1 (es) Compuestos y métodos para el tratamiento de las infecciones de candidiasis y aspergillus
DK3079655T3 (da) Inhalerbare lægemidler
BR112014011488A2 (pt) medicamento para tratamento terapêutico e/ou melhora de sépsis
CO6801728A2 (es) Formulación de lipomosas adecuada para tratar o prevenir la tuberculosis
EP2888260A4 (en) SUBSTITUTED AZAINDOLE COMPOUNDS, THEIR SALTS, THEIR PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE
BR112014015885A8 (pt) preparação farmacêutica
BR112013034066A2 (pt) método de administração e tratamento
BR112014001425A2 (pt) forma de dosagem farmacêutica, composição farmacêutica, e, composto (i) ou sal farmaceuticamente aceitável do mesmo
IL250201A0 (en) Administration of erythuran or its salts suitable for pharmaceutical use for the treatment of orthomyxovirus infections
BR112014020597A2 (pt) compostos para tratar infecção por parvovírus
BR112014008082A8 (pt) uso de aminopiridina ou de sais da mesma para fabricação de medicamentos para tratar deterioração relacionada com acidente vascular cerebral
BR112013030365A2 (pt) composições para administração percutânea de princípio ativo fisiologicamente
HUE044885T2 (hu) Hatóanyagok társítása topikális alkalmazásra bõrbetegségek utáni megváltozott bõr barrier újra strukturálására
SI2939665T1 (sl) Farmacevtska sestava za zdravljenje HIV infekcij
DK2897588T3 (da) Inhalerbart lægemiddel

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements